Search

Your search keyword '"Mataraza, Jennifer"' showing total 126 results
Start Over Author "Mataraza, Jennifer"
126 results on '"Mataraza, Jennifer"'

2. Supplementary Data Figures from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

Author

Dickinson, Michael J., primary, Barba, Pere, primary, Jäger, Ulrich, primary, Shah, Nirav N., primary, Blaise, Didier, primary, Briones, Javier, primary, Shune, Leyla, primary, Boissel, Nicolas, primary, Bondanza, Attilio, primary, Mariconti, Luisa, primary, Marchal, Anne-Laure, primary, Quinn, David S., primary, Yang, Jennifer, primary, Price, Andrew, primary, Sohoni, Akash, primary, Treanor, Louise M., primary, Orlando, Elena J., primary, Mataraza, Jennifer, primary, Davis, Jaclyn, primary, Lu, Darlene, primary, Zhu, Xu, primary, Engels, Boris, primary, Moutouh-de Parseval, Laure, primary, Brogdon, Jennifer L., primary, Moschetta, Michele, primary, and Flinn, Ian W., primary

Published
2023
Full Text
View/download PDF

3. Data from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

Author

Dickinson, Michael J., primary, Barba, Pere, primary, Jäger, Ulrich, primary, Shah, Nirav N., primary, Blaise, Didier, primary, Briones, Javier, primary, Shune, Leyla, primary, Boissel, Nicolas, primary, Bondanza, Attilio, primary, Mariconti, Luisa, primary, Marchal, Anne-Laure, primary, Quinn, David S., primary, Yang, Jennifer, primary, Price, Andrew, primary, Sohoni, Akash, primary, Treanor, Louise M., primary, Orlando, Elena J., primary, Mataraza, Jennifer, primary, Davis, Jaclyn, primary, Lu, Darlene, primary, Zhu, Xu, primary, Engels, Boris, primary, Moutouh-de Parseval, Laure, primary, Brogdon, Jennifer L., primary, Moschetta, Michele, primary, and Flinn, Ian W., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Data Tables from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

Author

Dickinson, Michael J., primary, Barba, Pere, primary, Jäger, Ulrich, primary, Shah, Nirav N., primary, Blaise, Didier, primary, Briones, Javier, primary, Shune, Leyla, primary, Boissel, Nicolas, primary, Bondanza, Attilio, primary, Mariconti, Luisa, primary, Marchal, Anne-Laure, primary, Quinn, David S., primary, Yang, Jennifer, primary, Price, Andrew, primary, Sohoni, Akash, primary, Treanor, Louise M., primary, Orlando, Elena J., primary, Mataraza, Jennifer, primary, Davis, Jaclyn, primary, Lu, Darlene, primary, Zhu, Xu, primary, Engels, Boris, primary, Moutouh-de Parseval, Laure, primary, Brogdon, Jennifer L., primary, Moschetta, Michele, primary, and Flinn, Ian W., primary

Published
2023
Full Text
View/download PDF

5. OA-06 Robust in vivo expansion and long-term persistence of anti-BCMA CAR T cells, PHE885, manufactured in <2 days on the T-Charge platform

Author

Ikegawa, Shuntaro, primary, Prabhala, Rao, additional, Sperling, Adam, additional, Nikiforow, Sarah, additional, Quinn, David, additional, Bu, Dexiu, additional, Mataraza, Jennifer, additional, Pearson, David, additional, Rispoli, Lawrence, additional, Credi, Marc, additional, Orwitz, Nina, additional, Potluri, Laksmi, additional, Arihara, Yohei, additional, Reynolds, Carol, additional, Ansuinelli, Michela, additional, Nguyen, Tuyet, additional, Vita, Serena, additional, Munshi, Nikhil, additional, and Ritz, Jerome, additional

Published
2023
Full Text
View/download PDF

6. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

Author

Dickinson, Michael J., primary, Barba, Pere, additional, Jäger, Ulrich, additional, Shah, Nirav N., additional, Blaise, Didier, additional, Briones, Javier, additional, Shune, Leyla, additional, Boissel, Nicolas, additional, Bondanza, Attilio, additional, Mariconti, Luisa, additional, Marchal, Anne-Laure, additional, Quinn, David S., additional, Yang, Jennifer, additional, Price, Andrew, additional, Sohoni, Akash, additional, Treanor, Louise M., additional, Orlando, Elena J., additional, Mataraza, Jennifer, additional, Davis, Jaclyn, additional, Lu, Darlene, additional, Zhu, Xu, additional, Engels, Boris, additional, Moutouh-de Parseval, Laure, additional, Brogdon, Jennifer L., additional, Moschetta, Michele, additional, and Flinn, Ian W., additional

Published
2023
Full Text
View/download PDF

7. Supplementary Table 1 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Author

Even, Caroline, primary, Wang, Hung-Ming, primary, Li, Shau-Hsuan, primary, Ngan, Roger K-C, primary, Dechaphunkul, Arunee, primary, Zhang, Li, primary, Yen, Chia-Jui, primary, Chan, Po Chung, primary, Chakrabandhu, Somvilai, primary, Ma, Brigette B.Y., primary, Tanasanvimon, Suebpong, primary, Lee, Victor H.F., primary, Lou, Pei-Jen, primary, Li, Zujun, primary, Spira, Alexander I., primary, Sukari, Ammar, primary, Guigay, Joël, primary, McCune, Steven, primary, Gonzalez-Maffe, Juan, primary, Szpakowski, Sebastian, primary, Yao, Yao, primary, Liang, Hongzi, primary, Mataraza, Jennifer, primary, Séchaud, Romain, primary, Manenti, Luigi, primary, and Lim, Darren W-T., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table 3 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Author

Even, Caroline, primary, Wang, Hung-Ming, primary, Li, Shau-Hsuan, primary, Ngan, Roger K-C, primary, Dechaphunkul, Arunee, primary, Zhang, Li, primary, Yen, Chia-Jui, primary, Chan, Po Chung, primary, Chakrabandhu, Somvilai, primary, Ma, Brigette B.Y., primary, Tanasanvimon, Suebpong, primary, Lee, Victor H.F., primary, Lou, Pei-Jen, primary, Li, Zujun, primary, Spira, Alexander I., primary, Sukari, Ammar, primary, Guigay, Joël, primary, McCune, Steven, primary, Gonzalez-Maffe, Juan, primary, Szpakowski, Sebastian, primary, Yao, Yao, primary, Liang, Hongzi, primary, Mataraza, Jennifer, primary, Séchaud, Romain, primary, Manenti, Luigi, primary, and Lim, Darren W-T., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Table 5 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Author

Even, Caroline, primary, Wang, Hung-Ming, primary, Li, Shau-Hsuan, primary, Ngan, Roger K-C, primary, Dechaphunkul, Arunee, primary, Zhang, Li, primary, Yen, Chia-Jui, primary, Chan, Po Chung, primary, Chakrabandhu, Somvilai, primary, Ma, Brigette B.Y., primary, Tanasanvimon, Suebpong, primary, Lee, Victor H.F., primary, Lou, Pei-Jen, primary, Li, Zujun, primary, Spira, Alexander I., primary, Sukari, Ammar, primary, Guigay, Joël, primary, McCune, Steven, primary, Gonzalez-Maffe, Juan, primary, Szpakowski, Sebastian, primary, Yao, Yao, primary, Liang, Hongzi, primary, Mataraza, Jennifer, primary, Séchaud, Romain, primary, Manenti, Luigi, primary, and Lim, Darren W-T., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 1 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Author

Even, Caroline, primary, Wang, Hung-Ming, primary, Li, Shau-Hsuan, primary, Ngan, Roger K-C, primary, Dechaphunkul, Arunee, primary, Zhang, Li, primary, Yen, Chia-Jui, primary, Chan, Po Chung, primary, Chakrabandhu, Somvilai, primary, Ma, Brigette B.Y., primary, Tanasanvimon, Suebpong, primary, Lee, Victor H.F., primary, Lou, Pei-Jen, primary, Li, Zujun, primary, Spira, Alexander I., primary, Sukari, Ammar, primary, Guigay, Joël, primary, McCune, Steven, primary, Gonzalez-Maffe, Juan, primary, Szpakowski, Sebastian, primary, Yao, Yao, primary, Liang, Hongzi, primary, Mataraza, Jennifer, primary, Séchaud, Romain, primary, Manenti, Luigi, primary, and Lim, Darren W-T., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 2 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Author

Even, Caroline, primary, Wang, Hung-Ming, primary, Li, Shau-Hsuan, primary, Ngan, Roger K-C, primary, Dechaphunkul, Arunee, primary, Zhang, Li, primary, Yen, Chia-Jui, primary, Chan, Po Chung, primary, Chakrabandhu, Somvilai, primary, Ma, Brigette B.Y., primary, Tanasanvimon, Suebpong, primary, Lee, Victor H.F., primary, Lou, Pei-Jen, primary, Li, Zujun, primary, Spira, Alexander I., primary, Sukari, Ammar, primary, Guigay, Joël, primary, McCune, Steven, primary, Gonzalez-Maffe, Juan, primary, Szpakowski, Sebastian, primary, Yao, Yao, primary, Liang, Hongzi, primary, Mataraza, Jennifer, primary, Séchaud, Romain, primary, Manenti, Luigi, primary, and Lim, Darren W-T., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table 4 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Author

Even, Caroline, primary, Wang, Hung-Ming, primary, Li, Shau-Hsuan, primary, Ngan, Roger K-C, primary, Dechaphunkul, Arunee, primary, Zhang, Li, primary, Yen, Chia-Jui, primary, Chan, Po Chung, primary, Chakrabandhu, Somvilai, primary, Ma, Brigette B.Y., primary, Tanasanvimon, Suebpong, primary, Lee, Victor H.F., primary, Lou, Pei-Jen, primary, Li, Zujun, primary, Spira, Alexander I., primary, Sukari, Ammar, primary, Guigay, Joël, primary, McCune, Steven, primary, Gonzalez-Maffe, Juan, primary, Szpakowski, Sebastian, primary, Yao, Yao, primary, Liang, Hongzi, primary, Mataraza, Jennifer, primary, Séchaud, Romain, primary, Manenti, Luigi, primary, and Lim, Darren W-T., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 3 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Author

Even, Caroline, primary, Wang, Hung-Ming, primary, Li, Shau-Hsuan, primary, Ngan, Roger K-C, primary, Dechaphunkul, Arunee, primary, Zhang, Li, primary, Yen, Chia-Jui, primary, Chan, Po Chung, primary, Chakrabandhu, Somvilai, primary, Ma, Brigette B.Y., primary, Tanasanvimon, Suebpong, primary, Lee, Victor H.F., primary, Lou, Pei-Jen, primary, Li, Zujun, primary, Spira, Alexander I., primary, Sukari, Ammar, primary, Guigay, Joël, primary, McCune, Steven, primary, Gonzalez-Maffe, Juan, primary, Szpakowski, Sebastian, primary, Yao, Yao, primary, Liang, Hongzi, primary, Mataraza, Jennifer, primary, Séchaud, Romain, primary, Manenti, Luigi, primary, and Lim, Darren W-T., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Table 7 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Author

Even, Caroline, primary, Wang, Hung-Ming, primary, Li, Shau-Hsuan, primary, Ngan, Roger K-C, primary, Dechaphunkul, Arunee, primary, Zhang, Li, primary, Yen, Chia-Jui, primary, Chan, Po Chung, primary, Chakrabandhu, Somvilai, primary, Ma, Brigette B.Y., primary, Tanasanvimon, Suebpong, primary, Lee, Victor H.F., primary, Lou, Pei-Jen, primary, Li, Zujun, primary, Spira, Alexander I., primary, Sukari, Ammar, primary, Guigay, Joël, primary, McCune, Steven, primary, Gonzalez-Maffe, Juan, primary, Szpakowski, Sebastian, primary, Yao, Yao, primary, Liang, Hongzi, primary, Mataraza, Jennifer, primary, Séchaud, Romain, primary, Manenti, Luigi, primary, and Lim, Darren W-T., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 2 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Author

Even, Caroline, primary, Wang, Hung-Ming, primary, Li, Shau-Hsuan, primary, Ngan, Roger K-C, primary, Dechaphunkul, Arunee, primary, Zhang, Li, primary, Yen, Chia-Jui, primary, Chan, Po Chung, primary, Chakrabandhu, Somvilai, primary, Ma, Brigette B.Y., primary, Tanasanvimon, Suebpong, primary, Lee, Victor H.F., primary, Lou, Pei-Jen, primary, Li, Zujun, primary, Spira, Alexander I., primary, Sukari, Ammar, primary, Guigay, Joël, primary, McCune, Steven, primary, Gonzalez-Maffe, Juan, primary, Szpakowski, Sebastian, primary, Yao, Yao, primary, Liang, Hongzi, primary, Mataraza, Jennifer, primary, Séchaud, Romain, primary, Manenti, Luigi, primary, and Lim, Darren W-T., primary

Published
2023
Full Text
View/download PDF

16. Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Author

Kuemmel, Sherko, primary, Campone, Mario, primary, Loirat, Delphine, primary, Lopez, Rafael Lopez, primary, Beck, J. Thaddeus, primary, De Laurentiis, Michelino, primary, Im, Seock-Ah, primary, Kim, Sung-Bae, primary, Kwong, Ava, primary, Steger, Guenther G., primary, Adelantado, Esther Zamora, primary, Duhoux, Francois P., primary, Greil, Richard, primary, Kuter, Irene, primary, Lu, Yen-Shen, primary, Tibau, Ariadna, primary, Özgüroğlu, Mustafa, primary, Scholz, Christian W., primary, Singer, Christian F., primary, Vega, Estela, primary, Wimberger, Pauline, primary, Zamagni, Claudio, primary, Couillebault, Xuan-Mai, primary, Fan, Liqiong, primary, Guerreiro, Nelson, primary, Mataraza, Jennifer, primary, Sand-Dejmek, Janna, primary, and Chan, Arlene, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Author

Kuemmel, Sherko, primary, Campone, Mario, primary, Loirat, Delphine, primary, Lopez, Rafael Lopez, primary, Beck, J. Thaddeus, primary, De Laurentiis, Michelino, primary, Im, Seock-Ah, primary, Kim, Sung-Bae, primary, Kwong, Ava, primary, Steger, Guenther G., primary, Adelantado, Esther Zamora, primary, Duhoux, Francois P., primary, Greil, Richard, primary, Kuter, Irene, primary, Lu, Yen-Shen, primary, Tibau, Ariadna, primary, Özgüroğlu, Mustafa, primary, Scholz, Christian W., primary, Singer, Christian F., primary, Vega, Estela, primary, Wimberger, Pauline, primary, Zamagni, Claudio, primary, Couillebault, Xuan-Mai, primary, Fan, Liqiong, primary, Guerreiro, Nelson, primary, Mataraza, Jennifer, primary, Sand-Dejmek, Janna, primary, and Chan, Arlene, primary

Published
2023
Full Text
View/download PDF

18. Data from Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

Author

Wang, Hui Qin, primary, Mulford, Iain J., primary, Sharp, Fiona, primary, Liang, Jinsheng, primary, Kurtulus, Sema, primary, Trabucco, Gina, primary, Quinn, David S., primary, Longmire, Tyler A., primary, Patel, Nidhi, primary, Patil, Roshani, primary, Shirley, Matthew D., primary, Chen, Yan, primary, Wang, Hao, primary, Ruddy, David A., primary, Fabre, Claire, primary, Williams, Juliet A., primary, Hammerman, Peter S., primary, Mataraza, Jennifer, primary, Platzer, Barbara, primary, and Halilovic, Ensar, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Data from Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

Author

Wang, Hui Qin, primary, Mulford, Iain J., primary, Sharp, Fiona, primary, Liang, Jinsheng, primary, Kurtulus, Sema, primary, Trabucco, Gina, primary, Quinn, David S., primary, Longmire, Tyler A., primary, Patel, Nidhi, primary, Patil, Roshani, primary, Shirley, Matthew D., primary, Chen, Yan, primary, Wang, Hao, primary, Ruddy, David A., primary, Fabre, Claire, primary, Williams, Juliet A., primary, Hammerman, Peter S., primary, Mataraza, Jennifer, primary, Platzer, Barbara, primary, and Halilovic, Ensar, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table 6 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Author

Even, Caroline, primary, Wang, Hung-Ming, primary, Li, Shau-Hsuan, primary, Ngan, Roger K-C, primary, Dechaphunkul, Arunee, primary, Zhang, Li, primary, Yen, Chia-Jui, primary, Chan, Po Chung, primary, Chakrabandhu, Somvilai, primary, Ma, Brigette B.Y., primary, Tanasanvimon, Suebpong, primary, Lee, Victor H.F., primary, Lou, Pei-Jen, primary, Li, Zujun, primary, Spira, Alexander I., primary, Sukari, Ammar, primary, Guigay, Joël, primary, McCune, Steven, primary, Gonzalez-Maffe, Juan, primary, Szpakowski, Sebastian, primary, Yao, Yao, primary, Liang, Hongzi, primary, Mataraza, Jennifer, primary, Séchaud, Romain, primary, Manenti, Luigi, primary, and Lim, Darren W-T., primary

Published
2023
Full Text
View/download PDF

21. Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

Author

Berry, Sneha, Giraldo, Nicolas, Nguyen, Peter, Green, Benjamin, Xu, Haiying, Ogurtsova, Aleksandra, Soni, Abha, Succaria, Farah, Wang, Daphne, Roberts, Charles, Stein, Julie, Engle, Elizabeth, Pardoll, Drew, Anders, Robert, Cottrell, Tricia, Taube, Janis M., Tran, Ben, Voskoboynik, Mark, Kuo, James, Bang, Yung-Lue, Chung, Hyun-Cheo, Ahn, Myung-Ju, Kim, Sang-We, Perera, Ayesh, Freeman, Daniel, Achour, Ikbel, Faggioni, Raffaella, Xiao, Feng, Ferte, Charles, Lemech, Charlotte, Meric-Bernstam, Funda, Werner, Theresa, Hodi, Stephen, Messersmith, Wells, Lewis, Nancy, Talluto, Craig, Dostalek, Mirek, Tao, Aiyang, McWhirter, Sarah, Trujillo, Damian, Luke, Jason, Xu, Chunxiao, BoMarelli, Qi, Jin, Qin, Guozhong, Yu, Huakui, Jenkins, Molly, Lo, Kin-Ming, Halle, Joern-Peter, Lan, Yan, Taylor, Matthew, Vogelzang, Nicholas, Cohn, Allen, Stepan, Daniel, Shumaker, Robert, Dutcus, Corina, Guo, Matthew, Schmidt, Emmett, Rasco, Drew, Brose, Marcia, Vogelzang, Nicholas, Di Simone, Christopher, Jain, Sharad, Richards, Donald, Encarnacion, Carlos, Rasco, Drew, Shumaker, Robert, Dutcus, Corina, Stepan, Daniel, Guo, Matthew, Schmidt, Emmett, Taylor, Matthew, Vogelzang, Nicholas, Encarnacion, Carlos, Cohn, Allen, Di Simone, Christopher, Rasco, Drew, Richards, Donald, Taylor, Matthew, Dutcus, Corina, Stepan, Daniel, Shumaker, Robert, Guo, Matthew, Schmidt, Emmett, Mier, James, An, Jeongshin, Yang, Yeun-yeoul, Lee, Won-Hee, Yang, Jinho, Kim, Jong-kyu, Kim, Hyun Goo, Paek, Se Hyun, Lee, Jun Woo, Woo, Joohyun, Kim, Jong Bin, Kwon, Hyungju, Lim, Woosung, Paik, Nam Sun, Kim, Yoon-Keun, Moon, Byung-In, Janku, Filip, Tan, David, Martin-Liberal, Juan, Takahashi, Shunji, Geva, Ravit, Gucalp, Ayca, Chen, Xueying, Subramanian, Kulandayan, Mataraza, Jennifer, Wheler, Jennifer, and Bedard, Philippe

Published
2019
Full Text
View/download PDF

24. Abstract 5186: Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial

Author

Jäger, Ulrich, primary, Han, Xia, additional, Germano, Davide, additional, Quinn, David, additional, Gaddis, Dalia, additional, Masood, Aisha, additional, Mulvey, Tanya, additional, Mataraza, Jennifer, additional, Bishop, Michael R., additional, Salles, Gilles, additional, Maziarz, Richard, additional, and Schuster, Stephen, additional

Published
2022
Full Text
View/download PDF

25. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Kuemmel, Sherko, Campone, Mario, Loirat, Delphine, Lopez, Rafael Lopez, Beck, J Thaddeus, De Laurentiis, Michelino, Im, Seock-Ah, Kim, Sung-Bae, Kwong, Ava, Steger, Guenther G, Adelantado, Esther Zamora, Duhoux, Francois, Greil, Richard, Kuter, Irene, Lu, Yen-Shen, Tibau, Ariadna, Özgüroğlu, Mustafa, Scholz, Christian W, Singer, Christian F, Vega, Estela, Wimberger, Pauline, Zamagni, Claudio, Couillebault, Xuan-Mai, Fan, Liqiong, Guerreiro, Nelson, Mataraza, Jennifer, Sand-Dejmek, Janna, Chan, Arlene, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Kuemmel, Sherko, Campone, Mario, Loirat, Delphine, Lopez, Rafael Lopez, Beck, J Thaddeus, De Laurentiis, Michelino, Im, Seock-Ah, Kim, Sung-Bae, Kwong, Ava, Steger, Guenther G, Adelantado, Esther Zamora, Duhoux, Francois, Greil, Richard, Kuter, Irene, Lu, Yen-Shen, Tibau, Ariadna, Özgüroğlu, Mustafa, Scholz, Christian W, Singer, Christian F, Vega, Estela, Wimberger, Pauline, Zamagni, Claudio, Couillebault, Xuan-Mai, Fan, Liqiong, Guerreiro, Nelson, Mataraza, Jennifer, Sand-Dejmek, Janna, and Chan, Arlene

Abstract

This phase II study determined the efficacy of lacnotuzumab added to gemcitabine plus carboplatin (gem-carbo) in patients with advanced triple-negative breast cancer (TNBC). Female patients with advanced TNBC, with high levels of tumor-associated macrophages not amenable to curative treatment by surgery or radiotherapy were enrolled. Lacnotuzumab was dosed at 10 mg/kg every 3 weeks, ± a dose on cycle 1, day 8. Gemcitabine (1,000 mg/m) and carboplatin (dose in mg calculated by area under the curve [mg/mL/min] × (glomerular filtration rate [mL/min] + 25 [mL/min]) were dosed every 3 weeks. Treatment continued until unacceptable toxicity, disease progression, or discontinuation by physician/patient. Patients received lacnotuzumab + gem-carbo ( = 34) or gem-carbo ( = 15). Enrollment was halted due to recruitment challenges owing to rapid evolution of the therapeutic landscape; formal hypothesis testing of the primary endpoint was therefore not performed. Median progression-free survival was 5.6 months [90% confidence interval (CI), 4.47-8.64] in the lacnotuzumab + gem-carbo arm and 5.5 months (90% CI, 3.45-7.46) in the gem-carbo arm. Hematologic adverse events were common in both treatment arms; however, patients treated with lacnotuzumab experienced more frequent aspartate aminotransferase, alanine aminotransferase, and creatine kinase elevations. Pharmacokinetic results showed that free lacnotuzumab at 10 mg/kg exhibited a typical IgG pharmacokinetic profile and target engagement of circulating colony-stimulating factor 1 ligand. Despite successful target engagement and anticipated pharmacokinetic profile, lacnotuzumab + gem-carbo showed comparable antitumor activity to gem-carbo alone, with slightly poorer tolerability. However, the data presented in this article would be informative for future studies testing agents targeting the CSF1-CSF1 receptor pathway in TNBC.

Published
2022

26. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Author

Kuemmel, Sherko, primary, Campone, Mario, additional, Loirat, Delphine, additional, Lopez, Rafael Lopez, additional, Beck, J. Thaddeus, additional, De Laurentiis, Michelino, additional, Im, Seock-Ah, additional, Kim, Sung-Bae, additional, Kwong, Ava, additional, Steger, Guenther G., additional, Adelantado, Esther Zamora, additional, Duhoux, Francois P., additional, Greil, Richard, additional, Kuter, Irene, additional, Lu, Yen-Shen, additional, Tibau, Ariadna, additional, Özgüroğlu, Mustafa, additional, Scholz, Christian W., additional, Singer, Christian F., additional, Vega, Estela, additional, Wimberger, Pauline, additional, Zamagni, Claudio, additional, Couillebault, Xuan-Mai, additional, Fan, Liqiong, additional, Guerreiro, Nelson, additional, Mataraza, Jennifer, additional, Sand-Dejmek, Janna, additional, and Chan, Arlene, additional

Published
2022
Full Text
View/download PDF

27. Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Author

Even, Caroline, primary, Wang, Hung-Ming, additional, Li, Shau-Hsuan, additional, Ngan, Roger K-C, additional, Dechaphunkul, Arunee, additional, Zhang, Li, additional, Yen, Chia-Jui, additional, Chan, Po Chung, additional, Chakrabandhu, Somvilai, additional, Ma, Brigette B.Y., additional, Tanasanvimon, Suebpong, additional, Lee, Victor H.F., additional, Lou, Pei-Jen, additional, Li, Zujun, additional, Spira, Alexander I., additional, Sukari, Ammar, additional, Guigay, Joël, additional, McCune, Steven, additional, Gonzalez-Maffe, Juan, additional, Szpakowski, Sebastian, additional, Yao, Yao, additional, Liang, Hongzi, additional, Mataraza, Jennifer, additional, Séchaud, Romain, additional, Manenti, Luigi, additional, and Lim, Darren W-T., additional

Published
2021
Full Text
View/download PDF

28. Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in &lt;2 Days Using the T-Charge TM Platform

Author

Sperling, Adam S., primary, Nikiforow, Sarah, additional, Nadeem, Omar, additional, Mo, Clifton C, additional, Laubach, Jacob P., additional, Anderson, Kenneth C., additional, Alonso, Alejandro, additional, Ikegawa, Shuntaro, additional, Prabhala, Rao, additional, Hernandez Rodriguez, Diego, additional, Daley, Heather, additional, Shaw, Kit L., additional, Arihara, Yohei, additional, Ansari, Soudeh, additional, Quinn, David S, additional, Pearson, David, additional, Hack, Anniesha, additional, Treanor, Louise M, additional, Bu, Dexiu, additional, Mataraza, Jennifer, additional, Rispoli, Lawrence, additional, Credi, Marc, additional, Ritz, Jerome, additional, De Vita, Serena, additional, and Munshi, Nikhil C., additional

Published
2021
Full Text
View/download PDF

29. A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

Author

Flinn, Ian W., primary, Jaeger, Ulrich, additional, Shah, Nirav N., additional, Blaise, Didier, additional, Briones, Javier, additional, Shune, Leyla, additional, Boissel, Nicolas, additional, Bondanza, Attilio, additional, Lu, Darlene, additional, Zhu, Xu, additional, Engels, Boris, additional, Brogdon, Jennifer L, additional, Mataraza, Jennifer, additional, Davis, Jaclyn, additional, Marchal, Anne Laure, additional, Mariconti, Luisa, additional, Moschetta, Michele, additional, Parseval, Laure Moutouh-de, additional, Barba, Pere, additional, and Dickinson, Michael, additional

Published
2021
Full Text
View/download PDF

31. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Author

Piha-Paul, Sarina A, primary, Geva, Ravit, additional, Tan, Tira J, additional, Lim, Darren WT, additional, Hierro, Cinta, additional, Doi, Toshikiko, additional, Rahma, Osama, additional, Lesokhin, Alexander, additional, Luke, Jason John, additional, Otero, Javier, additional, Nardi, Lisa, additional, Singh, Angad, additional, Xyrafas, Alexandros, additional, Chen, Xinhui, additional, Mataraza, Jennifer, additional, and Bedard, Philippe L, additional

Published
2021
Full Text
View/download PDF

33. T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabtagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity

Author

Ikegawa, Shuntaro, Sperling, Adam S., Ansuinelli, Michela, Nikiforow, Sarah, Quinn, David, Bu, Dexiu, Mataraza, Jennifer, Pearson, David, Rispoli, Lawrence, Credi, Marc A, Orwitz, Nina, Arihara, Yohei, Prabhala, Rao, Potluri, Lakshmi Bhavani, Reynolds, Carol, Vita, Serena De, Munshi, Nikhil C, and Ritz, Jerome

Published
2023
Full Text
View/download PDF

36. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

Author

Wang, Hui Qin, primary, Mulford, Iain J., additional, Sharp, Fiona, additional, Liang, Jinsheng, additional, Kurtulus, Sema, additional, Trabucco, Gina, additional, Quinn, David S., additional, Longmire, Tyler A., additional, Patel, Nidhi, additional, Patil, Roshani, additional, Shirley, Matthew D., additional, Chen, Yan, additional, Wang, Hao, additional, Ruddy, David A., additional, Fabre, Claire, additional, Williams, Juliet A., additional, Hammerman, Peter S., additional, Mataraza, Jennifer, additional, Platzer, Barbara, additional, and Halilovic, Ensar, additional

Published
2021
Full Text
View/download PDF

38. Abstract CT172: Pharmacodynamic and gene expression profiling of patients treated with BLZ945 + spartalizumab demonstrates on-target peripheral and tumor immune microenvironment modulation

Author

Wu, Jincheng, primary, Lin, Chia-Chi, additional, Gil-Martin, Marta, additional, Naing, Aung, additional, Fan, Liqiong, additional, Yang, Fang, additional, Quinn, David, additional, Tu, Pei-Jung, additional, Quadt, Cornelia, additional, and Mataraza, Jennifer, additional

Published
2020
Full Text
View/download PDF

39. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

Author

Naing, Aung, primary, Gainor, Justin F, additional, Gelderblom, Hans, additional, Forde, Patrick M, additional, Butler, Marcus O, additional, Lin, Chia-Chi, additional, Sharma, Sunil, additional, Ochoa de Olza, Maria, additional, Varga, Andrea, additional, Taylor, Matthew, additional, Schellens, Jan H M, additional, Wu, Hongqian, additional, Sun, Haiying, additional, Silva, Antonio P, additional, Faris, Jason, additional, Mataraza, Jennifer, additional, Cameron, Scott, additional, and Bauer, Todd M, additional

Published
2020
Full Text
View/download PDF

44. Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers

Author

Wang, Hui Qin, primary, Liang, Jinsheng, additional, Mulford, Iain, additional, Sharp, Fiona, additional, Gaulis, Swann, additional, Chen, Yan, additional, Trabucco, Gina, additional, Quinn, David, additional, Growney, Joseph D., additional, Meyer, Matthew J., additional, Williams, Juliet, additional, Hammerman, Peter, additional, Hofmann, Francesco, additional, Dranoff, Glenn, additional, Engelman, Jeffrey, additional, Mataraza, Jennifer, additional, and Halilovic, Ensar, additional

Published
2018
Full Text
View/download PDF

45. Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.

Author

Calvo, Aitana, primary, Joensuu, Heikki, additional, Sebastian, Martin, additional, Naing, Aung, additional, Bang, Yung-Jue, additional, Martin, Miguel, additional, Roda, Desamparados, additional, Hodi, F. Stephen, additional, Veloso, Artur, additional, Mataraza, Jennifer, additional, Baneyx, Guillaume, additional, Guerreiro, Nelson, additional, Liao, Serena, additional, Rabault, Bertrand, additional, Fjaellskog, Marie-Louise, additional, and Cervantes, Andres, additional

Published
2018
Full Text
View/download PDF

46. Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).

Author

Sperling, Adam Samuel, Derman, Benjamin Avi, Nikiforow, Sarah, Im, Soo-Yeon, Ikegawa, Shuntaro, Prabhala, Rao H., Rodriguez, Diego Hernandez, Li, Yifang, Quinn, David S., Pearson, David, Bu, Dexiu, Mataraza, Jennifer, Liegel, Jessica, D'Souza, Anita, Rispoli, Lawrence, Credi, Marc, Ritz, Jerome, Jakubowiak, Andrzej J., De Vita, Serena, and Munshi, Nikhil C.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results